Purpose To review the current therapeutic options for the management of diabetic
retinopathy (DR) and diabetic macular edema (DME) and examine the evidence for …

Intravitreal injections continue to be one of the most commonly performed procedures by
ophthalmologists. Although the injections are generally well tolerated, sight-threatening …

Diabetic retinopathy (DR) and age-related macular degeneration (AMD) are major causes of
blindness globally. The primary treatment option for DME and neovascular AMD (nAMD) is …

Diabetic retinopathy (DR) is the leading cause of blindness in working‐age adults. Severe
visual loss in DR is primarily due to proliferative diabetic retinopathy, characterized by …

Ophthalmic drug delivery to the posterior segment of the eye has been challenging due to
the complex ocular anatomy. Intravitreal injection of drugs was introduced to deliver …

A narrative review on the association of high intraocular pressure and glaucoma in patients
with retinal vein occlusion - PMC Back to Top Skip to main content NIH NLM Logo Access keys …

Diabetic retinopathy (DR) is a highly tissue-specific neurovascular complication of type 1
and type 2 diabetes mellitus and is among the leading causes of blindness worldwide …

Purpose To compare the visual and morphological effects between intravitreal injection of
filtered modified 2 mg triamcinolone acetonide (TA) and 0. 5 mg ranibizumab in patients with …

To evaluate outcomes of intravitreal bevacizumab (IVB) treating macular edema (ME) after
retinal vein occlusion (RVO) following pro re nata (PRN) regimen and investigate potential …

Purpose To evaluate a new chronic glaucoma model produced by intracameral injection of
dexamethasone-loaded poly lactic-co-glycolic acid microspheres (Dex-PLGA-Ms) over six …